Introduction {#s1}
============

Age is one of the most important risk factors for chronic kidney disease (CKD). In the United States, the prevalence of an estimated glomerular filtration rate (eGFR) of \<60 ml/min/1.73 m^2^ increases from 0.9% to 51.2% with an increase in age from \<60 years to ≥80 years \[[@B1]\]. However, it is debatable whether mildly decreased eGFR without definite evidence of renal damage, such as proteinuria or azotemia-related complications, should be considered an indicator of "disease" in the elderly population \[[@B2]\]. The reason for using an eGFR of 60 ml/min/1.73 m^2^ as a threshold value in the diagnoses of CKD is that eGFR \< 60 ml/min/1.73 m^2^ is related to higher prevalence of CKD complications. In a prospective cohort study of 1,038 hospital inpatients, the eGFR thresholds used for detecting CKD complications were 50, 44, 40, 39, and 37 ml/min/1.73 m^2^ for hyperparathyroidism, anemia, acidosis, hyperkalemia, and hyperphosphatemia, respectively \[[@B3]\]. However, most of the study included relatively young patients, and thus its results may not be generalizable to the elderly population. In an examination of age-specific associations between eGFR and concurrent CKD complications by analysis of cross-sectional data collected from the National Health and Nutrition Examination Survey (NHANES) from 1988 to 1994 and from 1999 to 2006, Bowling et al. concluded that decreased eGFR is associated with a higher prevalence of CKD complications, regardless of age \[[@B4]\]. However, their use of a cross-sectional design did not allow for evaluation of the temporal association between decreased eGFR and CKD complications \[[@B4]\]. So, we constructed this study in order to verify the association between eGFR and concurrent CKD complications and elucidate the temporal relationship between incident CKD and new CKD complications in a community-based prospective elderly cohort.

Methods {#s2}
=======

Design of KLoSHA {#s2.1}
----------------

This study was conducted as a part of the Korean Longitudinal Study on Health and Aging (KLoSHA), which included a randomly selected, community-based, elderly population \[[@B5]\]. The KLoSHA protocol was approved by the Institutional Review Board of Seoul National University Bundang Hospital (SNUBH) in 2005 and 2010 and accorded with the Declaration of Helsinki. The duration of the follow-up period was 59.4 ± 6.9 months. After obtaining written informed consent from all participants, the assessments were performed at SNUBH. Among the 1,000 original KLoSHA subjects, 984 subjects who were not dependent on renal replacement therapy and had a baseline value of glomerular filtration rate were selected for participation in this study ([Figure 1](#pone-0084467-g001){ref-type="fig"}).

![The participants in this study from the KLoSHA cohort.](pone.0084467.g001){#pone-0084467-g001}

Clinical characteristics {#s2.2}
------------------------

The data regarding all medications taken by the participants were collected. Diabetes mellitus (DM) and hypertension were defined as they had been elsewhere \[[@B5]\]. The serum creatinine level was measured by the alkaline picrate Jaffe kinetic method using an automatic analyzer (Toshiba 200FR; Tokyo, Japan). Serum creatinine levels were calibrated to an assay traceable on an isotope dilution mass spectrometry (IDMS) device (Roche Diagnostics). GFR was calculated using the CKD-epidemiology collaboration (CKD-EPI) equation \[[@B6]\]. The participants were categorized into 6 GFR groups: group 1, GFR ≥ 90 ml/min/1.73 m^2^; group 2, 75--89 ml/min/1.73 m^2^; group 3, 60--74 ml/min/1.73 m^2^; group 4, 45--59 ml/min/1.73 m^2^; group 5, 30--44 ml/min/1.73 m^2^; and group 6, \<30 ml/min/1.73 m^2^. CKD was defined as a GFR \< 60 ml/min/1.73 m^2^. Anemia was defined as a hemoglobin level \< 12 g/dL in women and \<13 g/dL in men \[[@B7]\]. Nutrient deficiencies were defined as follows: iron deficiency as the total iron-binding capacity (TIBC) saturation rate \< 15% \[[@B8]\], ferritin deficiency as a ferritin level \< 12 ng/ml \[[@B8]\], vitamin B12 deficiency as a B12 level \< 200 pg/ml \[[@B9]\], and folate deficiency as a folate level \< 2.6 ng/ml \[[@B9]\]. Hypertriglyceridemia was defined as serum triglyceride levels ≥ 150 mg/dL, hypoalbuminemia as serum albumin levels \< 3.5 g/dL, hyperkalemia as serum potassium levels \> 5.5 mEq/L, and acidosis as total CO~2~ \< 22 mmol/L.

Outcomes {#s2.3}
--------

The duration of the follow-up period was 59.4 ± 6.9 months. Complications related to CKD were defined as hypertension, hypertriglyceridemia, hypoalbuminemia, hyperkalemia, acidosis, and anemia. Incident CKD was diagnosed in patients who experienced GFR decrease from ≥60 ml/min/1.73 m^2^ at baseline examination to \<60 ml/min/1.73 m^2^ at second examination and persistent CKD in patients who had GFR \<60 ml/min/1.73 m^2^ at both baseline and second examination. Newly developed CKD complications were detected at second examination.

Statistical analyses {#s2.4}
--------------------

All analyses were performed using SPSS software (SPSS version 20.0, Chicago, IL). Data were presented as the mean ± SD values for continuous variables and as proportions for categorical variables. Differences in continuous variables were analyzed by one-way analysis of variance or Student *t*-test according to the number of subgroups, and differences in categorical variables were analyzed by Pearson's chi-square or Fisher's exact test. The levels of potassium, total CO~2~, and hemoglobin and the number of complications at baseline examination were estimated by analysis of co-variance (ANCOVA), adjusted by the factors related to each parameter. The risk factors for concurrent CKD complications, incident CKD, persistent CKD, and newly developed CKD complications during follow-up were identified by multiple logistic regression analysis. Formal testing for interactions between GFR groups and aging for each complication was conducted by comparing --2 log likelihood in regression models with and without the interaction term (GFR group\*age in a 10-year unit).

Results {#s3}
=======

Basal characteristics {#s3.1}
---------------------

The patient sample (N = 984) included 436 men (44.3%) and 548 women (55.7%) with a mean age of 76.0 ± 9.1 years and a mean estimated GFR of 72.3 ± 17.0 ml/min/1.73 m^2^. The number of participants in each GFR group was as follows: 150 (15.2%) in group 1 (GFR ≥ 90 ml/min/1.73 m^2^), 348 (35.4%) in group 2 (GFR 75--89 ml/min/1.73 m^2^) 249 (25.3%) in group 3 (GFR 60--74 ml/min/1.73 m^2^), 161 (16.4%) in group 4 (GFR 45--59 ml/min/1.73 m^2^), 59 (6.0%) in group 5 (GFR 30--44 ml/min/1.73 m^2^), and 17 (1.5%) in group 6 (GFR \<30 ml/min/1.73 m^2^; [Table 1](#pone-0084467-t001){ref-type="table"}).

10.1371/journal.pone.0084467.t001

###### Basal characteristics of elderly population at 1^st^ examination according to GFR.

                                GFR group   p-value                                                     
  ----------------------------- ----------- ----------- ----------- ----------- ----------- ----------- ---------
  Number                        150         348         249         161         59          17          
  Age (years)                   69.2±5.2    74.6±8.3    76.2±8.3    81.9±9.8    82.7±8.0    83.0±7.0    \<0.001
  Gender (Male, %)              33.3        42.8        47.0        54.0        42.4        47.1        0.012
  DBP (mmHg)                    83±10       84±10       82±10       82±11       80±12       84±14       0.171
  SBP (mmHg)                    133±18      133±18      131±16      133±19      131±23      136±22      0.831
  History of cancer (%)         8.8         5.5         6.9         10.0        5.2         5.9         0.476
  Smoking (%)                                                                                           0.001
  Never                         71.3        61.8        54.2        49.1        57.6        70.6        
  Ex-smoker                     16.7        25.9        33.3        39.1        39.0        23.5        
  Current smoker                12.0        12.4        12.4        11.8        3.4         5.9         
  DM (%)                        24.0        23.6        24.5        22.4        27.1        29.4        0.971
  Hypertension (%)              67.3        72.4        72.7        77.6        84.7        94.1        0.032
  Glucose (mg/dL)               110±30      110±27      108±22      106±21      103±24      105±21      0.325
  HbA1c (%)                     6.1±1.0     6.0±0.8     6.0±0.8     6.0±0.7     6.0±0.6     6.0±1.2     0.932
  Albumin (g/dL)                4.1±0.2     4.1±0.3     4.1±0.2     4.1±0.2     4.1±0.3     4.0±0.3     0.167
  Cholesterol (mg/dL)           205±38      203±38      202±39      201±34      203±40      194±40      0.869
  Triglyceride (mg/dL)          143±108     129±80      138±81      133±1       127±46      135±63      0.496
  Creatinine (mg/dL)            0.65±0.11   0.79±0.13   0.94±0.13   1.12±0.15   1.41±0.23   2.49±1.50   \<0.001
  GFR (ml/min/1.73 m^2^)        94.1±5.0    82.2±4.9    68.0±4.1    54.4±4.1    39.7±3.8    24.2±7.0    \<0.001
  CRP (mg/dL)                   0.21±0.56   0.24±0.65   0.22±0.49   0.24±0.52   0.61±1.71   0.14±0.22   0.003
  TIBC saturation (%)           30.8±12.7   32.1±13.7   33.3±12.4   30.7±10.6   27.9±10.3   30.4±16.3   0.038
  Ferritin (ng/mL)              107±151     121±116     119±98      125±104     128±131     147±115     0.672
  Vitamin B12 (pg/ml)           629±322     667±927     639±347     687±995     617±343     979±849     0.521
  Hemoglobin (g/dL)             13.7±1.4    13.8±1.5    13.9±1.4    13.6±1.5    12.7±1.5    12.4±1.2    \<0.001
  Proteinuria by dipstick (%)                                                               \<0.001     
  None                          89.6        86.8        86.3        77.1        63.8        56.3        
  trace                         4.9         6.6         7.5         13.4        15.5        6.3         
  1+ or more                    5.6         6.6         6.2         9.5         20.7        37.6        
  Hematuria (%)                 7.6         10.5        11.7        10.2        10.3        25.0        0.394
  Medication (%)                                                                                        
  ACEI or ARB                   8.7         11.2        13.7        17.4        25.4        52.9        \<0.001
  Anti-platelet agent           11.3        17.8        24.1        23.6        28.8        47.1        0.001
  Antidiabetic medication       10.7        10.3        12.9        13.7        15.3        23.5        0.488
  Statin                        5.3         7.2         8.4         10.6        10.2        5.9         0.584
  No.of anti-HTN (%)            37.3        44          44.6        50.3        62.7        94.1        \<0.001
  1                             26.0        30.5        26.9        29.8        32.2        41.2        
  2                             7.3         9.8         9.6         13.0        13.6        29.4        
  3                             3.3         3.4         6.8         5.0         13.6        5.9         
  \>3                           0.7         0.3         1.2         2.4         3.4         17.6        

GFR: Calculated by CKD-EPI equation, , GFR groups; group 1: ≥ 90, group 2: 75-89, group 3: 60-74, group 4 : 45-59, group 5: 30-44, and group 6 : \< 30 ml/min/1.73 m^2^, BMI: body mass index, CRP: c-reactive protein, TIBC: Total iron binding capacity, Proteinuria: measured by dipstick test, Hematuria: RBC ≥ 5/HPF, Diabetic medication: oral hypoglycemic agent, insulin, and/or others, No. of anti-HTN: number of anti-hypertensive medication

Complications at baseline {#s3.2}
-------------------------

With decrease of GFR level, higher prevalence of hypertension, anemia, hyperkalemia, or acidosis were notified ([Figure 2](#pone-0084467-g002){ref-type="fig"}). The odds ratio (OR) for hypertension increased in GFR group 4, group 5, and group 6, for anemia, in GFR group 5 and group 6, for acidosis or hyperkalemia, in GFR group 6, compared to GFR group 1 ([Table 2](#pone-0084467-t002){ref-type="table"}). There were mild positive interactions between GFR group and age for hypertension (p-interaction=0.046) but, not for acidosis, anemia, hypoalbuminemia, and hyperkalemia. The estimated hemoglobin was higher in GFR group 2 or group 3 than in group 1, although, that was lower in Group 5 or group 6 ([Figure 3](#pone-0084467-g003){ref-type="fig"}). The estimated potassium level in group 6 was lower than in other groups (p\<0.001). The estimated total CO~2~ started to decrease from GFR 60 ml/min/1.73 m^2^ (p\<0.001). The estimated number of complications adjusted with related factors was 0.98 (0.88-1.09) in GFR group 1, 1.11 (1.05-1.17) in group 2, 1.09 (1.02-1.17) in group 3, 1.16 (1.06-1.26) in group 4, 1.48 (1.32-1.64) in group 5, and 2.12 (1.83-2.41) in group 6 (p\<0.001) ([Figure 3](#pone-0084467-g003){ref-type="fig"}).

![The prevalence of complications related to renal dysfunction.\
P-value calculated by Pearson's Chi-square test. HyperTG: hypertriglyceridemia.](pone.0084467.g002){#pone-0084467-g002}
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###### The odds ratio for complications in GFR groups at basal examination.

                         B        Wald     OR       95% CI for OR   p-value   
  ---------------------- -------- -------- -------- --------------- --------- ---------
  Hypertension^1^                 19.375                                      0.002
  GFR group 1 vs 2       0.444    3.032    1.558    0.946           2.567     0.082
  GFR group 1 vs 3       0.475    3.134    1.607    0.950           2.719     0.077
  GFR group 1 vs 4       0.860    7.927    2.363    1.299           4.298     0.005
  GFR group 1 vs 5       1.647    12.378   5.191    2.074           12.995    \<0.001
  GFR group 1 vs 6       2.614    5.745    13.657   1.611           115.806   0.017
  Anemia^2^                       31.997                                      \<0.001
  GFR group 1 vs 2       0.459    0.694    1.583    0.537           4.663     0.405
  GFR group 1 vs 3       -0.155   0.063    0.856    0.255           2.872     0.801
  GFR group 1 vs 4       0.919    2.250    2.508    0.754           8.336     0.134
  GFR group 1 vs 5       2.059    10.562   7.842    2.265           27.153    0.001
  GFR group 1 vs 6       2.566    11.324   13.019   2.920           58.047    0.001
  Acidosis^3^                     30.231                                      \<0.001
  GFR group 1 vs 2       0.419    0.130    1.521    0.156           14.806    0.718
  GFR group 1 vs 3       0.379    0.095    1.461    0.131           16.342    0.758
  GFR group 1 vs 4       0.219    0.024    1.245    0.077           20.255    0.878
  GFR group 1 vs 5       2.203    3.543    9.054    0.913           89.779    0.060
  GFR group 1 vs 6       4.242    12.736   69.580   6.770           715.147   \<0.001
  Hyperkalemia^4^                 12.179                                      0.032
  GFR group 1 vs 2       0.093    0.007    1.098    0.130           9.262     0.932
  GFR group 1 vs 3       -0.052   0.002    0.950    0.098           9.218     0.965
  GFR group 1 vs 4       -0.216   0.025    0.805    0.055           11.745    0.874
  GFR group 1 vs 5       0.789    0.330    2.200    0.149           32.396    0.566
  GFR group 1 vs 6       2.954    5.983    19.177   1.798           204.474   0.014
  CKD complication^5^             14.801                                      0.005
  GFR group 1 vs 2       0.496    3.119    1.643    0.947           2.850     0.077
  GFR group 1 vs 3       0.634    4.363    1.884    1.040           3.414     0.037
  GFR group 1 vs 4       0.635    3.486    1.887    0.969           3.676     0.062
  GFR group 1 vs 5 & 6   2.285    13.400   9.828    2.891           33.407    \<0.001

Hypertension^1^: Odds ratio of GFR group for hypertension, adjusted with age, gender, SBP, DBP, DM, and levels of serum albumin, alanine aminotransferase, cholesterol, triglyceride, HbA1c, TIBC, WBC, and platelet.

Anemia^2^: Odds ratio of GFR group for anemia, adjusted with age, gender, SBP, DBP, number of anti-hypertensive medication, deficiency of ferritin, presence of anti-HBV surface antibody, and levels of serum albumin, alanine aminotransferase, bilirubin, Gamma-glutamyl transferase, cholesterol, triglyceride, CRP, HbA1c, TIBC saturation rate, activated prothrombin time, and WBC.

Acidosis^3^: Odds ratio of GFR group for acidosis, adjusted with age, gender, and presence of proteinuria ≥1+.

Hyperkalemia^4^: Odds ratio of GFR group for hyperkalemia, adjusted with age, gender, serum bilirubin, thyroxin 4, TIBC,and LDH

CKD complication^5^ : Odds ratio of GFR group, in which group 5 and 6 were combined because of lack of subjects without complication in group 6, for presence of CKD complications, adjusted with age, gender, SBP, DBP, glucose, albumin, alkaline phosphatase, alanine aminotransferase, gamma-glutamyl transferase, cholesterol, HDL-cholesterol, triglyceride, TIBC, WBC, platelet, ESR.

The factor of GFR group was not related to hypoalbuminemia and hypertriglyceridemia by mulitple logistic regression adjusted with other risk factors. CKD complications included anemia, acidosis, hyperkalemia, hypoalbuminemia, hypertriglyceridemia, and hypertension.

GFR groups; group 1: ≥ 90, group 2: 75-89, group 3: 60-74, group 4 : 45-59, group 5: 30-44, and group 6 : \< 30 ml/min/1.73 m^2^

![Estimated hemoglobin level (A), serum potassium level (B), total CO~2~ level (C), and number of complications (D) according to GFR group at basal examination by ANCOVA.\
\*p \< 0.05, different from GFR group 1; \*\*p \< 0.05, different from other GFR groups; \*\*\*p \< 0.05, different from GFR groups 1, 2, and 3. The level of hemoglobin was adjusted by age; sex; SBP; DBP; number of anti-hypertensive medications; ferritin deficiency; presence of anti-HBV surface antibodies; levels of serum albumin, alanine aminotransferase, bilirubin, gamma-glutamyl transferase, cholesterol, triglyceride, CRP, and HbA1c; TIBC saturation rate; activated prothrombin time; and WBC count. The level of serum potassium was adjusted by age; sex; levels of serum bilirubin, thyroxin 4, and LDH; and TIBC saturation rate. The level of total CO~2~ was adjusted by age, sex, and presence of proteinuria ≥ 1+. The number of complications was adjusted by age; sex; SBP; DBP; levels of glucose, albumin, alkaline phosphatase, alanine aminotransferase, gamma-glutamyl transferase, cholesterol, HDL-cholesterol, triglycerides; TIBC saturation rate; WBC and platelet count; and ESR.](pone.0084467.g003){#pone-0084467-g003}

Incident and persistent CKD {#s3.3}
---------------------------

Among 354 participants who had a GFR ≥ 60 ml/min/1.73 m^2^ at basal examination, 34 developed CKD (9.6%) during a 5-year observational period. The risk of incident CKD was found to be 5.896-fold higher in group 3 as compared to group 1 (p = 0.006). Each 10-mmHg increase in SBP was found to increase risk of incident CKD by 1.331-fold (95% CI: 1.087--1.629) ([Table 3](#pone-0084467-t003){ref-type="table"}). Compared to participants without incident CKD, the prevalence of anemia (9/36 vs. 25/318 participants; p = 0.001) and number of CKD complications (1.58 ± 0.61 vs. 1.13 ± 0.72 complications; p = 0.001) were found to be higher in participants with incident CKD. Among 59 subjects with a GFR \< 60 ml/min/1.73 m^2^ at basal examination, GFR increased to ≥60 ml/min/1.73 m^2^ in 20 (33.9%). Although 46.3% (19/41) of participants with GFR of 45--59 ml/min/1.73 m^2^ at basal examination had a GFR ≥60 ml/min/1.73 m^2^ at second examination, only 5.6% (1/18) who had a GFR \<45 ml/min/1.73 m^2^ at baseline had the above mentioned GFR at the second examination (p = 0.002). The number of CKD complications at the second examination was higher in participants with persistent CKD than in participants with GFR who experienced a GFR increase to over 60 mL/min/1.73 m^2^ (1.79 ± 0.96 vs. 1.00 ± 0.65; p = 0.001).

10.1371/journal.pone.0084467.t003

###### The risk factors for incident CKD or persistent CKD among subjects with follow-up examination.

                                                                                      B       RR       95% CI for RR   p-value   
  ------------------------------------------------------ ---------------------------- ------- -------- --------------- --------- -------
  Incident CKD[\*](#ngtab3.1){ref-type="table-fn"}       GFR (ml/min/1.73 m^2^)                                                  0.010
                                                         ≥ 90 vs 74-89                0.995   2.705    0.730           10.028    0.137
                                                         ≥ 90 vs 60-74                1.781   5.934    1.671           21.075    0.006
                                                         SBP (mmHg)                                                              0.007
                                                         \<130 vs 130-149             0.526   1.692    0.659           4.349     0.275
                                                         \<130 vs ≥150                1.447   4.251    1.661           10.883    0.003
  Persistent CKD[\*\*](#ngtab3.2){ref-type="table-fn"}   GFR \< 45 ml/min/1.73 m^2^   1.896   6.661    0.645           68.805    0.111
                                                         Age (year)                   0.151   1.163    1.047           1.292     0.005
                                                         DM (presence)                3.579   35.854   2.223           578.167   0.012
                                                         Bilirubin (mg/dL)            3.994   0.018    0.001           0.384     0.010

^\*^ Incident CKD: The relative risk for GFR \<60 ml/min/1.73 m^2^ at 2^nd^ examination was analyzed among participants with GFR ≥60 ml/min/1.73 m^2^ at basal examination, which was estimated with adjustment by age, gender, DM, hypertension, SBP, presence of proteinuria ≥ 1+, and GFR (≥ 90, 75-89, and 60-74 ml/min/1.73 m^2^) at baseline examination.

^\*\*^ Persistent CKD: The relative risk for GFR \<60 ml/min/1.73 m^2^ at 2^nd^ examination was analyzed among participants with GFR \<60 ml/min/1.73 m^2^ at basal examination, which was estimated with adjustment by age, gender, DM, hypertension, presence of proteinuria ≥ 1+, bilirubin, hemoglobin, and GFR (≥ 45 and \< 45 ml/min/1.73 m^2^) at baseline examination.

Newly developed CKD complications {#s3.4}
---------------------------------

Among the 354 subjects who had a GFR ≥ 60 ml/min/1.73 m^2^ at basal examination, 90 (25.4%) developed at least one new complication during the follow-up period. These included 40 (11.3%) subjects who developed incident hypertriglyceridemia; 27 (7.6%), incident anemia; 17 (4.8%), incident hypertension; 5 (1.4%), incident hyperkalemia; 3 (0.8%), incident acidosis; and 3 (0.8%), incident hypoalbuminemia. Simple logistic regression analysis indicated that incident CKD increases the risk of developing anemia (relative risk \[RR\]: 4.874, 95% CI: 1.946--12.208, p = 0.001) and hyperkalemia (RR: 6.604, 95% CI: 1.064--40.995, p = 0.043), and multiple regression analysis indicated that incident CKD increases the risk of developing new complications by 2.792-fold (95% CI: 1.308--5.964). ANCOVA adjusted by related factors for development of new CKD complications indicated that subjects with incident CKD developed 0.52 (95% CI: 0.35--0.68) new complications, while subjects without incident CKD developed 0.24 (95% CI: 0.19--0.29; p = 0.002) new complications. Among participants with a GFR ≥ 60 ml/min/1.73 m^2^ at baseline examination, a threshold GFR of 52.4 ml/min/1.73 m^2^ at second examination was found to predict development of any CKD complication with 90% sensitivity (p = 0.032 by ROC analysis).

Discussion {#s4}
==========

In the cohort examined in this study, the concurrent prevalence of hypertension increased at a threshold GFR of \<60 ml/min/1.73 m^2^, anemia at GFR \< 45 ml/min/1.73 m^2^, and both acidosis and hyperkalemia at GFR \< 30 ml/min/1.73 m^2^. The rate of incident CKD, as defined by the criterion value of GFR of 60 ml/min/1.73 m^2^, was 9.6% over the 5-year study period. The rate of the incident CKD was found to increase the incidence of anemia and hyperkalemia and the total number of newly developed complications, while improvement in GFR was found to result in improvement of the severity of complications.

Several reports have suggested that a decrease in GFR in older subjects increases the risk for metabolic complications associated with CKD. However, these reports were limited in their analysis of the temporal associations between complications and decrease in GFR because of cross-sectional or retrospective study design \[[@B4],[@B10]\]. The KLoSHA offered several advantages in this respect, being based on analysis of data representative of a city population collected from non-institutionalized inhabitants selected by random sampling. A prospective study, the KLoSHA, provides higher-quality evidence and allows for analysis of the temporal relationship between incident CKD and complications. In addition, the KLoSHA measured serum creatinine levels in a single institution throughout the study period.

The results of this study confirm the existence of a relationship between the concurrent CKD complications and a decrease in GFR without any interactions between GFR and the aging process, indicating that a decrease in GFR attributable to the aging process may not be responsible for these complications. When we adopt the criteria for GFR group (≥60, 45-59, \<45 ml/min/1.73 m^2^), the higher prevalence of anemia, acidosis, hyperkalemia, hypertension, and CKD complication as a whole were consistently present at GFR levels \<45 ml/min/1.73 m^2^ as the results of elderly subjects from NHANES data \[[@B4]\]. Overall number of concurrent complications related to CKD started to increase at GFR \<60 ml/min/1.73 m^2^ which was comparable to the Gubbio study in Italy \[[@B11]\].

Although the changes in total CO~2~ and potassium levels and number of complications observed with a decrease in GFR were linear, the changes observed in the estimated hemoglobin level were non-linear. Specifically, the results of ANCOVA revealed that estimated hemoglobin levels increased with a decrease in GFR, beginning at an initial GFR of 90 ml/min/1.73 m^2^ until it reached 45 ml/min/1.73 m^2^ and then began to decrease with a continued decrease in GFR, a pattern that we had observed in a younger population \[[@B12]\]. Such a phenomenon could not be related to iron, vitamin B12, or folate deficiency because the prevalence of deficiency did not differ according to the GFR decline. A pattern of changes in hemoglobin level was also observed in subjects without nutrient deficiency ([Figure S1](#pone.0084467.s001){ref-type="supplementary-material"}), which might correlate with the findings of early research into erythropoietin and creatinine clearance \[[@B13]\]. Specifically, hematocrit and erythropoietin levels were found to slightly increase with a decrease in creatinine clearance from 90 to approximately 45 ml/min, and the erythropoietin level of patients with a high BMI and DM was found to be 22--55% higher than that of patients without these disorders \[[@B14]\]. These findings suggest that a slight increase in the hemoglobin level, associated with a minor decrease in GFR beginning at a GFR of 90 up till 60 ml/min/1.73 m^2^ and/or cardio-renal risk factors, may result from an increase in renal hypoxia aggravated by pre-existing conditions \[[@B15]\].

As in a previous study \[[@B4]\], hypoalbuminemia was not found to be related to GFR in the present study. Hypertriglyceridemia in end-stage renal disease is accompanied by impaired clearance of triglyceride-rich lipoproteins caused by dysregulation of lipoprotein lipase, hepatic lipase, or the very low-density lipoprotein receptor \[[@B16]\]. However, as the prevalence of hypertriglyceridemia depends on the severity of renal dysfunction, it tends not to increase in cases of mild-to-moderate CKD \[[@B17]\]. Another factor in the prevalence of hypertriglyceridemia related to CKD is the extent of proteinuria. Although significant proteinuria results in a significant increase in triglyceride synthesis \[[@B18]\], the prevalence of significant proteinuria (≥ 2+) was minimal (2.8%) in the population examined in the present study.

GFR and SBP were reported as the most important risk factors of incident CKD in previous reports \[[@B15],[@B19],[@B20]\]. In non-diabetic elderly subjects of the Cardiovascular Health Study Cohort, the OR for increase of serum creatinine ≥0.3 mg/dL was found to be 1.16 for every 10 mmHg increase in SBP \[[@B19]\]. In community-based cohort studies \[[@B19],[@B21]\], baseline renal function was found to be an independent factor for renal dysfunction or incident CKD. In the present study, subjects with incident CKD were found to have a higher number of concurrent complications and newly developed complications than subjects without CKD at second examination, a finding that provides good evidence of the existence of a positive temporal relationship between CKD and the number and frequency of complications. Using the criterion of GFR of 60 ml/min/1.73 m^2^ to define CKD, the incidence of anemia and hyperkalemia was found to have significantly increased at the second examination. Moreover, a significant difference in the number of complications was found between subjects with persistent CKD and with improved CKD, whose GFR had increased to ≥60 ml/min/1.73 m^2^ from \<60 ml/min/1.73 m^2^. Although it is debatable whether "improved CKD" can be defined by an improvement in serum creatinine levels at the second examination, suggested imprecision of creatinine-based GFR compared to cystatin-based GFR within a GFR range of 45 to 59 ml/min/1.73 m^2^ for predicting outcomes \[[@B22]\], and lack of validation of CKD-EPI equation in older population, the significant decrease of number of complications according to increase of GFR from \<60 ml/min/1.73 m^2^ to ≥60 ml/min/1.73 m^2^ should be notified.

There are several limitations to be considered in the interpretation of the results of this study. First, the study attempted to follow-up the participants for 5 years, but 30.5% of the initial sample could not be followed up at the second examination. Second, the CKD-EPI equation has not been fully validated for use with elderly Koreans, although a study of 131 CKD patients and healthy volunteers found that the ethnic coefficient of the MDRD equation using IDMS-traceable creatinine value was close to 1 \[[@B23]\]. Third, serum creatinine was measured once at each examination, which could provoke a bias for classification with estimated GFR. Fourth, in the analysis of anemia, causes other than renal dysfunction could have been responsible for it, although the analysis was adjusted for iron, vitamin B12, and folate deficiency. Finally, as this study examined an urban population, the extent to which the results can be generalized to a nationwide population or all Asians is debatable.

In conclusion, measurement of GFR and use of the recommended criteria for diagnosis of CKD were found useful in the predicting concurrent as well as incident complications related to renal dysfunction in an elderly cohort, as was found in younger populations. Clinicians should attempt to identify complications related to CKD in older patients experiencing a mild-to-moderate decrease in GFR.
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**Hemoglobin level according to GFR group in subjects without iron, vitamin B12, or folate deficiency.** The hemoglobin level was estimated by ANCOVA adjusted by factors related to hemoglobin level. Among 892 subjects without nutrient deficiency, hemoglobin level in subjects with a GFR \> 90 ml/min/1.73 m^2^ was lower than that in subjects with a GFR of 60--74 ml/min/1.73 m^2^ (^\*^p = 0.038), but higher than that in subjects with a GFR of 30--44 ml/min/1.73 m^2^ (^\*\*^p = 0.001) and those with a GFR \< 30 ml/min/1.73 m^2^ (^\*\*\*^p = 0.015).

(TIF)

###### 

Click here for additional data file.
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